Terminated NA INTERVENTIONAL 1-arm NCT00587847

Campath Maintenance in Chronic Lymphocytic Leukemia

Maintenance Alemtuzumab in Refractory Chronic Lymphocytic Leukemia

Sponsor: Bayer

Interventions Campath

Updated 7 times since 2017 Last updated: Sep 16, 2015 Started: Aug 31, 2005 Primary completion: Nov 30, 2009 Completion: Nov 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Insufficient recruitment.

Other terminated trials from Bayer

See all terminations from Bayer

Other Chronic Lymphocytic Leukemia trials with similar outcome

Browse all Chronic Lymphocytic Leukemia trials

This NA trial investigates Chronic Lymphocytic Leukemia and is currently terminated or withdrawn. Bayer leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Dec 2021 — Jul 2024 [monthly]

Terminated NA
Jan 2021 — Dec 2021 [monthly]

Terminated NA
Jun 2018 — Jan 2021 [monthly]

Terminated NA

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated NA
Jan 2017 — Feb 2017 [monthly]

Terminated NA

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Northwell Health

Data source: Northwell Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Hyde Park, United States